Double-blinded, Placebo-controlled Randomized Study Evaluating the Efficacy of Risedronate to Prevent the Loss of Bone Mineral Density in Non-metastatic Prostate Cancer Patients Undergoing Radiotherapy Plus 2-3 Years of Androgen Ablation Therapy